| Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies C Li, S Vandersluis, C Holubowich, WJ Ungar, ES Goh, KM Boycott, ... Genetics in Medicine 23 (3), 451-460, 2021 | 43 | 2021 |
| Cost‐Effectiveness of magnetic resonance‐guided focused ultrasound for essential tremor C Li, O Gajic‐Veljanoski, AK Schaink, C Higgins, A Fasano, N Sikich, ... Movement Disorders 34 (5), 735-743, 2019 | 26 | 2019 |
| COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada AS Ismaila, N Risebrough, C Li, D Corriveau, N Hawkins, JM FitzGerald, ... Respiratory medicine 108 (9), 1292-1302, 2014 | 24 | 2014 |
| Cost‐effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies O Gajic‐Veljanoski, C Li, AK Schaink, J Guo, N Shehata, GS Charames, ... Transfusion 62 (5), 1089-1102, 2022 | 5 | 2022 |
| Noninvasive fetal RhD blood group genotyping: a systematic review of economic evaluations O Gajic-Veljanoski, C Li, AK Schaink, J Guo, C Higgins, N Shehata, ... Journal of Obstetrics and Gynaecology Canada 43 (12), 1416-1425. e5, 2021 | 3 | 2021 |
| Coverage with evidence development activities around the world: an environment scan CM Li, NA Risebrough, M Hux Value in Health 17 (7), A449, 2014 | 3 | 2014 |
| A Note About Terminology M Mohamed, C Soulodre, S Harrison, J McKane, E Smitko, S McDowell, ... | 2 | 2022 |
| Correspondence on “cost or price of sequencing? implications for economic evaluations in genomic medicine” by Grosse and Gudgeon C Li, S Vandersluis, C Holubowich, WJ Ungar, ES Goh, KM Boycott, ... Genetics in Medicine 24 (1), 251-252, 2022 | 1 | 2022 |
| Pharmacoeconomic evaluation of denosumab for the treatment of bone metastases in patients with advanced breast cancer in Canada MJ Habib, N Risebrough, P Moore, R Kendall, CM Li, R Goeree CANCER RESEARCH 73, 2013 | 1 | 2013 |
| Developing a cross-validation tool for evaluating economic evidence in rapid literature reviews X Xie, C Li, S Tiggelaar, F Simbulan, L Falk, JM Brophy Journal of Comparative Effectiveness Research 11 (16), 1151-1160, 2022 | | 2022 |
| Maternal-child health crisis: Building the leadership framework for effective global interventions BB Tigges, CM Li, ST Harrison | | 2020 |
| BUDGET IMPACT ANALYSIS OF THE CELL CYCLE PROGRESSION TEST IN LOW AND INTERMEDIATE RISK, LOCALIZED PROSTATE CANCER C Li, AK Schaink, C Holubowich, N Sikich, I Dhalla, V Ng VALUE IN HEALTH 20 (5), A240-A240, 2017 | | 2017 |
| WHAT MAKES A GOOD ECONOMIC EVALUATION IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REVIEW OF REIMBURSEMENT SUBMISSIONS TO PCODR AND NICE CM Li, NA Risebrough, A Briggs Value in Health 19 (3), A86-A87, 2016 | | 2016 |
| Robot-assisted Radical Prostatectomy: a Cost-Utility Analysis X Xie, C Li, M Wang, C Higgins, N Sikich, I Dhalla, V Ng Lancet 388, 1057-66, 2016 | | 2016 |
| Abstract P6-07-02: Pharmacoeconomic evaluation of denosumab for the treatment of bone metastases in patients with advanced breast cancer in Canada MJ Habib, N Risebrough, P Moore, R Kendall, CM Li, R Goeree Cancer Research 73 (24_Supplement), P6-07-02-P6-07-02, 2013 | | 2013 |
| A Note About Terminology M Mohamed, C Soulodre, S Harrison, J McKane, E Smitko, S McDowell, ... | | |
